Jagsonpal Pharmaceuticals Ltd
Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India)
Ph.: +91 124 4406710; E-mail: info@jagsonpal.com; Website: www.jagsonpal.com
CIN. : L74899DL1978PLC009181

A CSR Initiative

July 29, 2026

The Department of Corporate Services- Listing **BSE Ltd,** Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 **Scrip Code: 507789**	The Department of Corporate Services- Listing **National Stock Exchange of India Ltd** Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 **Symbol: JAGSNPHARM**

Subject: Outcome of Board Meeting held on July 29, 2026 along with Unaudited (Standalone) Financial Results for the quarter June 30, 2026

Dear Sir/ Madam,

Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, Unaudited Financial Results for the quarter ended June 30, 2026.

In this regard, kindly find enclosed the Unaudited Financial Results along with its Limited Review Report issued by the Statutory Auditors of the Company for the quarter ended June 30, 2026.

The Board Meeting commenced at 03:45 p.m. and concluded at 04:17 p.m.

We request you to take the above on record.

Thanking you,

For **Jagsonpal Pharmaceuticals Limited**

PRATHAM RAWAL Digitally signed by PRATHAM RAWAL Date: 2026.07.29 16:51:30 +05'30'

Pratham Rawal

Company Secretary & Compliance officer

Walker Chandiok &Co LLP

Walker Chandiok & Co LLP
21st Floor, DLF Square
Jacaranda Marg, DLF Phase II
Gurugram – 122 002
India

T +91 124 4628099
F +91 124 4628001

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of Jagsonpal Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jagsonpal Pharmaceuticals Limited

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Jagsonpal Pharmaceuticals Limited ('the Company') for the quarter ended 30 June 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

WALKER CHANDIOK & CO LLP
CHARTERED ACCOUNTANTS

Walker Chandiok & Co LLP

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of Jagsonpal Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Madhu Sudan

Madhu Sudan Malpani
Partner
Membership No. 517440

WALKER CHANDIOK & CO LLP CHARTERED ACCOUNTANTS

UDIN: 26517440NJFRTQ2097

Place: Gurugram
Date: 29 July 2026

Jagsonpal Pharmaceuticals Limited

Registered office: Innov8 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi, 110020

Corporate office: Plot No. 412-415,3rd Floor, Nimai Tower, Phase- IV, Udyog Vihar, Sector 18, Gurugram, Haryana-122015

CIN No:- L74899DL1978PLC009181

Phone: 0124-4406710

Statement of Unaudited Financial Results for the Quarter Ended 30 June 2026

(Rs. in Million)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June (Unaudited) 2026	31 March (Audited) 2026	30 June (Unaudited) 2025	31 March (Audited) 2026
	INCOME				
1	Revenue from operations	822.32	642.03	756.12	2,872.25
2	Other income	28.33	31.68	28.25	119.95
3	Total income (1+2)	850.65	673.71	784.37	2,992.20
4	**EXPENSES**				
	a) Cost of materials consumed	48.66	29.87	53.32	161.13
	b) Purchases of stock-in-trade	260.50	198.88	226.89	891.88
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(22.92)	8.92	(10.94)	(9.26)
	d) Employee benefits expense	227.78	155.45	194.41	707.40
	e) Finance costs	2.51	2.52	2.54	10.28
	f) Depreciation and amortisation expenses	21.42	23.19	23.53	94.44
	g) Other expenses	135.90	137.32	150.31	540.36
	Total expenses	673.85	556.15	640.06	2,396.23
5	Profit before exceptional items and tax (3-4)	176.80	117.56	144.31	595.97
6	Exceptional items (net) (Refer Note 3)	-	-	-	(20.79)
7	Profit before tax (5+6)	176.80	117.56	144.31	575.18
8	Tax expense:				
	Current tax (including earlier years)	41.78	24.60	31.71	131.87
	Deferred tax charge	3.13	5.34	4.65	12.49
9	Net profit for the period/year (7-8)	131.89	87.62	107.95	430.82
10	**Other comprehensive income (OCI)**				
	i) a) Items that will not be reclassified to profit or loss	1.26	1.47	0.76	4.86
	b) Income tax relating to items that will not be reclassified to profit or loss	(0.32)	(0.37)	(0.19)	(1.22)
	ii) a) Items that will be reclassified to profit or loss	-	-	-	-
	b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
11	**Total comprehensive income for the period/year (9+10)**	**132.83**	**88.72**	**108.52**	**434.46**
12	Earnings per share (not annualised for the quarters)				
	Basic (Rs.)	2.00	1.25	1.60	6.40
	Diluted (Rs.)	1.98	1.21	1.58	6.31
13	Paid-up equity share capital (face value per share Rs. 2)	131.68	133.93	133.06	133.93
14	Reserves excluding revaluation reserves (other equity)				2,627.79
	See accompanying notes to the Unaudited Financial Results				

WALKER CHANDIOK & CO LLP ★ CHARTERED ACCOUNTANTS ★

SIGNED FOR IDENTIFICATION PURPOSES ONLY

Jagsonpal Pharmaceuticals Limited ★ Gurugram

Notes to the unaudited financial results:

1. The unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

2. The Company is primarily engaged in manufacturing and trading of pharmaceutical products (including active pharmaceutical ingredients) to its customers in India and overseas, which is being considered as a single reportable business segment by the chief operating decision maker.

3. During the previous year, effective 21 November 2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising of four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020, collectively referred to as the 'New Labour Codes'. The enactment of these codes has resulted in changes to the computation of certain employee benefits. The Company has assessed the impact of these changes in accordance with Ind AS 19 – Employee Benefits and the guidance issued by the Institute of Chartered Accountants of India (ICAI). The resulting additional employee benefit expense of ₹ 20.79 million, being material and non-recurring, has been presented under "Exceptional Items" in the financial results for the year ended 31 March 2026. During the quarter, on 08 May 2026, the Central Government notified the Code of Wages (Central) Rules, 2026 and the Company is currently evaluating the consequential impact of these Rules. The Company continues to monitor developments pertaining to the Labour Codes and will provide appropriate accounting impact on the basis of such developments as needed.

4. During the quarter, under the Company's Employee Stock Option Plan 2022, the Company has granted 153,000 stock options to the eligible employees as determined by the Nomination and Remuneration Committee and has allotted 473,220 equity shares on exercise of vested stock options by eligible employees.

5. The figures for the quarter ended 31 March 2026, as reported in the financial results, are the balancing figures between the audited figures for the year ended 31 March 2026 and the published year to date figures for 31 December 2025, which were subjected to limited review by the statutory auditors.

6. The Board of Directors, at their meeting held on 27 April 2026, has recommended a final dividend of ₹ 4 per equity share (of ₹ 2 each) for the year ended 31 March 2026 subject to approval in Annual General Meeting.

7. During the quarter, pursuant to the approvals of the Board of Directors and the shareholders, the Company undertook a buy-back of up to 1,600,000 equity shares of ₹ 2 each at a price of ₹ 250 per share for an aggregate consideration not exceeding ₹ 400 million through the tender offer route in accordance with the Companies Act, 2013 and the SEBI (Buy-Back of Securities) Regulations, 2018

8. During the quarter, the Company entered into a Share Purchase Agreement on 29 June 2026 to acquire an 85% equity stake in Aequitas Healthcare Private Limited for a consideration of ₹ 208 million, proposed to be funded through internal accruals. The existing promoters/directors will retain a 15% shareholding and continue to manage the business. While the Share Purchase Agreement was executed during the quarter, the transfer of shares and completion of closing formalities, including execution of the completion certificate, were completed subsequently in July 2026 and therefore did not have any impact on the financial results of the Company for the quarter ended 30 June 2026.

9. The above financial results for the quarter ended 30 June 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 29 July 2026 and a limited review of the same has been carried out by the statutory auditors.

Place : Gurugram
Date : 29 July 2026

Manish Gupta
Managing Director

WALKER CHANDIOK & CO LLP
CHARTERED ACCOUNTANTS

SIGNED FOR
IDENTIFICATION
PURPOSES ONLY

Jagsonpal Pharmaceuticals Limited
Gurugram